Yüklüyor......
Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme
BACKGROUND: Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis (UC). AIM: To report incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE) in the tofacitinib UC programme. METHODS: DVT and PE were evaluated from one phase 2 and two phase 3 induc...
Kaydedildi:
| Yayımlandı: | Aliment Pharmacol Ther |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
John Wiley and Sons Inc.
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6899755/ https://ncbi.nlm.nih.gov/pubmed/31599001 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.15514 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|